US IPO Pipeline SEC S-1 Filings — June 25, 2026

Affiliated operating expenses declined 1.7% YoY ($118M to $116M) in 2025, showing modest cost control, but Q1 2026 expenses were flat YoY at $32M, indicating stabilization

Short-term cash investments dropped 29.4% from $17M (Dec 2025) to $12M (Mar 2026), signaling reduced liquidity and potential cash burn

No public market exists for its stock, and the S-1 is for resale of 821,917 shares by two institutional holders (Castle Creek, EJF Sidecar), indicating these investors are seeking an exit after a 7.5-year holding period (since Dec 2018)

The company will receive zero proceeds from the offering, suggesting no new capital for growth and reliance on existing operations

NYSE listing under ticker 'REF' signals a high-profile consumer IPO, but the preliminary filing lacks share count and price range, creating uncertainty on valuation

Selling stockholders are participating alongside the company, which could pressure stock price post-IPO if large blocks are sold

Zero revenue from commercial activities despite being incorporated in 1998 (27 years ago), highlighting a long pre-revenue development phase and high cash burn risk

FDA Fast Track designation for CELZ-201-DDT and Orphan Drug Designation for CELZ-100 provide regulatory validation and potential market exclusivity, a bullish catalyst if trials succeed

Patient recruitment for Type 1 Diabetes trial (CELZ-201 CREATE-1) began September 2023, indicating clinical progress but no timeline for completion or data readout

3 out of 4 filings involve selling shareholders (Lincoln, Reformation, Creative), suggesting IPO market is being used for liquidity events rather than growth capital

Cash reserves fell 29.4% in one quarter ($17M to $12M), which could impair ability to fund operations or meet debt obligations

No existing public market for shares means price discovery is uncertain; the 821,917-share resale could face low demand

Two institutional holders (Castle Creek, EJF Sidecar) control the entire offering, creating potential for coordinated selling pressure

Preliminary S-1 lacks key details (share count, price range, financials), making it impossible to assess valuation or fundamentals

Zero revenue since incorporation in 1998; the company has no path to profitability without successful drug approvals, which may take years

IPO will likely involve significant dilution given pre-revenue status and need for capital to fund trials

Patient recruitment for Type 1 Diabetes trial began Sep 2023 but no update on enrollment completion; delays could derail timelines

3 of 4 filings involve selling shareholders, which typically signals insider desire to exit and can depress post-IPO performance

Sustainable fashion brand listing on NYSE could attract ESG-focused investors; if revenue growth is strong, it may command a premium valuation similar to other direct-to-consumer IPOs

FDA Fast Track and Orphan Drug designations reduce regulatory risk and could accelerate approval; if CELZ-201 succeeds in Type 1 Diabetes, it addresses a multi-billion-dollar market

As a community bank with no public market, the IPO could unlock value if the bank has strong local deposits and loan growth; institutional holders (Castle Creek, EJF) suggest professional backing

Flat operating expenses and affiliation with FirstEnergy (FE) provide stability; the S-4 business combination could create synergies and cost savings

The iPSC program represents cutting-edge regenerative medicine; if platform proves versatile, it could attract partnership or acquisition interest from larger pharma

30-day greenshoe option for additional shares suggests strong underwriter confidence; if demand is high, the stock could pop on debut

The Dec 2018 agreement with selling shareholders implies a long-term relationship; if the bank performs well, institutional holders may retain stakes, reducing selling pressure

3 of 4 filings (Lincoln, Reformation, Creative) include selling shareholders, indicating the IPO market is being used for liquidity events by early investors rather than primary capital formation. This suggests a mature pipeline where companies are already well-capitalized but insiders seek exits.

Creative Medical Technology exemplifies the high-risk/high-reward biotech IPO model, with zero revenue but multiple regulatory designations. This pattern is common in the sector but carries elevated failure risk.

Jersey Central Power & Light shows stable operating expenses but declining cash reserves, highlighting the tension between cost control and liquidity management in regulated utilities.

Reformation Inc. represents the only consumer-facing IPO in the batch, with NYSE listing signaling ambition. Consumer IPOs often attract retail and ESG investors, but the lack of financials in the preliminary filing creates uncertainty.

Lincoln Bancorp's filing shows that small bank IPOs continue to surface, but the absence of a public market and reliance on institutional selling shareholders suggests limited retail demand for such offerings.

Watch for amended S-1 with share count and price range; expected within weeks. Key to valuation assessment [Date: TBD]

Patient recruitment status for CELZ-201 CREATE-1 trial; any enrollment completion or data readout could be a major catalyst [Date: TBD]

S-1 declared effective by SEC; watch for trading debut and price discovery for the 821,917-share resale [Date: TBD]

S-4 related to FirstEnergy (FE) common equity; watch for shareholder vote and closing of the deal [Date: TBD]

Amended S-1 with share count and price range; will determine dilution and valuation [Date: TBD]

Watch for SEC comments and amendments to S-1/S-4 filings; delays could push back timelines [Date: Ongoing]

30-day greenshoe option; if exercised, indicates strong demand and potential for stock appreciation [Date: Post-IPO]